Boston Scientific Corporation $BSX Shares Sold by AIA Group Ltd

AIA Group Ltd lowered its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 7.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 105,465 shares of the medical equipment provider’s stock after selling 8,790 shares during the period. AIA Group Ltd’s holdings in Boston Scientific were worth $10,297,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in BSX. Norges Bank acquired a new stake in shares of Boston Scientific during the 2nd quarter worth about $2,089,937,000. Edgewood Management LLC purchased a new position in shares of Boston Scientific during the second quarter valued at approximately $746,655,000. Parnassus Investments LLC boosted its position in Boston Scientific by 42,978.9% during the third quarter. Parnassus Investments LLC now owns 6,884,440 shares of the medical equipment provider’s stock worth $672,128,000 after acquiring an additional 6,868,459 shares during the last quarter. Egerton Capital UK LLP raised its holdings in Boston Scientific by 223.7% in the 3rd quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider’s stock valued at $518,660,000 after acquiring an additional 3,671,548 shares during the last quarter. Finally, Jennison Associates LLC lifted its stake in shares of Boston Scientific by 133.5% during the 3rd quarter. Jennison Associates LLC now owns 4,938,746 shares of the medical equipment provider’s stock worth $482,170,000 after purchasing an additional 2,823,744 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on BSX. Wells Fargo & Company lowered their price objective on Boston Scientific from $125.00 to $94.00 and set an “overweight” rating for the company in a research report on Thursday, February 5th. Royal Bank Of Canada dropped their price objective on shares of Boston Scientific from $130.00 to $115.00 and set an “outperform” rating for the company in a research note on Thursday, February 5th. Stifel Nicolaus decreased their target price on shares of Boston Scientific from $125.00 to $110.00 and set a “buy” rating on the stock in a research report on Wednesday, February 4th. Weiss Ratings downgraded shares of Boston Scientific from a “buy (b-)” rating to a “hold (c+)” rating in a report on Wednesday, February 4th. Finally, Oppenheimer cut their price target on shares of Boston Scientific from $125.00 to $100.00 and set an “outperform” rating on the stock in a research note on Friday, January 16th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, Boston Scientific currently has a consensus rating of “Buy” and an average target price of $107.18.

Boston Scientific Price Performance

BSX opened at $71.29 on Thursday. The company has a fifty day simple moving average of $80.88 and a 200 day simple moving average of $92.56. The firm has a market cap of $105.78 billion, a price-to-earnings ratio of 36.75, a PEG ratio of 1.00 and a beta of 0.69. Boston Scientific Corporation has a twelve month low of $67.56 and a twelve month high of $109.50. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. The firm had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The firm’s revenue was up 15.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.70 EPS. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Equities research analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific’s European urology portfolio expanded with sacral neuromodulation following the Axonics deal, supporting recurring revenue growth in a defensive medtech category. Sacral neuromodulation broadening Boston Scientific’s European urology portfolio
• Positive Sentiment: Analysts continue to rate BSX as a buy: UBS and Truist trimmed price targets (UBS $120→$105; Truist $95→$92) but retained buy ratings, signaling ongoing analyst conviction even after downward target adjustments. Benzinga analyst notes
• Neutral Sentiment: Coverage pieces position Boston Scientific as a defensive healthcare hedge versus cyclically sensitive sectors, which can attract flows in volatile markets but is not an immediate catalyst. The Highest-Rated Healthcare Stock to Buy Now
• Neutral Sentiment: Industry hires and competitor moves (e.g., Field Medical naming a new CEO with Medtronic experience) are notable for competitive dynamics but are not direct, immediate earnings catalysts for BSX. Field Medical appoints Mark Turco as CEO
• Negative Sentiment: Multiple law firms and plaintiff notices warn Boston Scientific investors of a securities‑class‑action covering purchases from July 23, 2025 to Feb 3, 2026, with a May 4, 2026 lead‑plaintiff deadline — this surge of legal filings/notices increases potential litigation risk and uncertainty. Rosen Law Firm investor alert
• Negative Sentiment: Specific allegations (highlighted by firms such as Levi & Korsinsky) claim executives misrepresented U.S. electrophysiology procedure volumes — if proven, these allegations could lead to meaningful financial and reputational impact. Levi & Korsinsky investor alert

Insider Activity

In related news, CEO Michael F. Mahoney sold 160,901 shares of the stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 0.50% of the company’s stock.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.